MaxCyte

MaxCyte FCF per Share

The Free Cash Flow per Share of MaxCyte (MXCT) as of Oct 20, 2026 is -0.34 USD. In the previous year, Free Cash Flow per Share was -0.28 USD — a change of 21.80% (lower).

FCF per Share

-0.34USD

YoY

21.80%

Last updated:

Free Cash Flow per Share of MaxCyte is 2025 -0.34 USD. Free Cash Flow per Share of MaxCyte was 2024 -0.28 USD. It decreases by 21.80% lower compared to the previous year.

The MaxCyte FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-0.22 USD
Jan 1, 2019
-0.18 USD
Jan 1, 2020
-0.14 USD
Jan 1, 2021
-0.14 USD
Jan 1, 2022
-0.33 USD
Jan 1, 2023
-0.24 USD
Jan 1, 2024
-0.28 USD
Jan 1, 2025
-0.34 USD
The MaxCyte FCF per Share history
YEARFCF per ShareYoY
-0.34USD+21.80%
-0.28USD+14.00%
-0.24USD-24.84%
-0.33USD+126.26%
-0.14USD+2.23%
-0.14USD-19.74%
-0.18USD-19.64%
-0.22USD+7.99%
-0.20USD+245.30%
-0.06USD-59.64%
-0.15USD-97.02%
-4.86USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Free Cash Flow per Share of MaxCyte is -0.34 USD in 2025.

Free Cash Flow per Share of MaxCyte changed from -0.28 USD to -0.34 USD, representing a 21.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share MaxCyte since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — MaxCyte

All Key Metrics — MaxCyte